Rezolute Inc is trading 11.3% up at $4.45 today, driven by positive interim data from its Phase 3 upLIFT study and a significant price target increase from Guggenheim. - The company reported that six of eight participants in the upLIFT registrational study met the primary endpoint by significantly reducing IV glucose infusion requirements, with all responders discontinuing IV glucose support. - Guggenheim analyst Debjit Chattopadhyay raised the price target for Rezolute Inc to $11.00 from $6.00, citing the high likelihood of a positive readout from the upLIFT study. - The stock is also benefiting from a broad risk-on tape in U.S. markets.